24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Medical Disorders
Resources
Basic InformationLookupsLatest News
Hot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansCDC Opens Emergency Operations Center for Congo Ebola OutbreakScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. CitiesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyOpioids Put Alzheimer's Patients at Risk of Pneumonia: StudyHealth Tip: Early Signs of Lyme DiseaseHealth Tip: Hiccup Home RemediesSheep Study Shows a Stuffy Side Effect of VapingShould Air Quality Checks Be Part of Your Travel Planning?Health Tip: Preventing Swimmer's EarHeartburn Drugs Again Tied to Fatal RisksHealth Tip: Nasal Spray SafetyFDA Approves First Drug to Help Tame Cluster HeadachesMany Dietary Supplements Dangerous for TeensAverage American Ingests 70,000 Bits of Microplastic Each YearFalls Are Increasingly Lethal for Older AmericansChicken No Better Than Beef for Your Cholesterol?Another Use for Beta Blockers? Curbing A-fibCaffeine, Nicotine Withdrawal Can Cause Problems in the ICU: StudyYounger Gout Patients Have Higher Odds for Blood ClotsFDA Approves First Test for Zika in Human BloodCDC Warns Again of Salmonella From Pet HedgehogsWhy Some Kids With Eczema Are at Higher Allergy RiskMany Heart Failure Patients Might Safely Reduce Use of DiureticsU.S. Measles Cases for 2019 Already Exceed All Annual Totals Since 1992: CDCForget Fasting Before That Cholesterol TestU.S. Cancer Cases, Deaths Continue to Fall'Controlled Burns' Better for Kids' Health Than Wildfires: StudyHighly Processed Diets Tied to Heart Disease, Earlier DeathHealth Tip: Signs of Irritable Bowel SyndromeA Less Invasive Fix Works Well for Abdominal AneurysmFace Transplants Improve Lives Years Later
Questions and AnswersLinks
Related Topics

Diabetes

FDA Approves First Gene Therapy for Spinal Muscular Atrophy


HealthDay News
Updated: May 28th 2019

new article illustration

TUESDAY, May 28, 2019 (HealthDay News) -- The first gene therapy has been approved to treat children younger than 2 years with spinal muscular atrophy (SMA), the U.S. Food and Drug Administration announced Friday.

Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy, targets the cause of SMA by delivering a fully functional copy of the human SMN1 gene into the target motor neuron cells. According to the FDA, a one-time intravenous administration of the drug yields expression of the SMN protein in a child's motor neurons, which improves movement, function, and survival. Dosing is based on patient weight, with a recommended dosage of 1.1 × 1.014 vector genomes per kilogram of body weight. Zolgensma is administered as an intravenous infusion for 60 minutes.

Approval was based on two clinical trials, one ongoing. The completed clinical trial involved 36 children with infantile-onset SMA who were 2 weeks to 8 months old at study initiation. In the ongoing clinical trial, which initially included 21 patients, the 19 remaining patients are 9.4 to 18.5 months old. These patients have demonstrated significant improvement in reaching developmental motor milestones compared with the natural history of patients with infantile-onset SMA.

Commonly reported side effects include elevated liver enzymes and vomiting. A boxed warning included with the prescribing information indicates the risk for acute serious liver injury and warns that patients with preexisting liver impairment may be at higher risk. Before initiating treatment with Zolgensma and for at least three months after administration, clinicians should assess patients' liver function through clinical examination and laboratory testing. Patients should also be administered an oral corticosteroid before and after Zolgensma infusion; because certain vaccines are contraindicated for patients taking a corticosteroid, caregivers should consult with clinicians to determine if adjustments to the child's immunization schedule are necessary.

Approval of Zolgensma was granted to AveXis.

More Information